Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 study

Ryan C. Lynch, Ryan D. Cassaday, Stephen D. Smith, Jonathan R. Fromm, Andrew J. Cowan, Edus H. Warren, Mazyar Shadman, Andrei R. Shustov, Brian G. Till, Chaitra S. Ujjani, Edward N. Libby, Mary Philip, Hilary Coye, Christen N. Martino, Sandra L Bhark, Karolyn Morris, Heather Rasmussen, Fatemeh Behnia, Jenna Voutsinas, Ajay K. Gopal